Sanofi Invests $25 Million in China’s Adagene to Advance SAFEbody Program
French pharmaceutical major Sanofi (NASDAQ: SNY) is set to make a USD 25 million investment...
NHSA Unveils Plans for 2025 National Drug List Adjustments and Commercial Insurance Drug List
This week, China’s National Healthcare Security Administration (NHSA) released two draft documents detailing a plan...
Esteve to Acquire Sanofi’s Caprelsa Rights in Over 50 Countries for Medullary Thyroid Cancer Treatment
Spanish multinational pharmaceutical company Esteve, which also operates an industrial site in China, is set...
AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate
US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...
Chia Tai Tianqing’s Anlotinib Granted NMPA Approval for Soft Tissue Sarcoma
China-based Chia Tai Tianqing Pharmaceutical announced that its anlotinib (trade name: FOCUS V) has received...
Huadong Medicine’s First-in-Class ADC HDM2012 Gains FDA Phase I Trial Clearance
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clearance from the...
China Unveils Measures to Boost Innovative Drug Development With Insurance Data Support
China’s National Healthcare Security Administration (NHSA) and National Health Commission (NHC) jointly released the “Several...
HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...
Recbio Partners with Biological E for HPV VaccineREC603’s India and Global Expansion
China-based Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced a licensing agreement with India-headquartered Biological...
Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...
Guangdong Announces First Batch of Approved Innovative Drugs and Medical Devices
Departments including the Department of Industry and Information Technology, Health Commission, Healthcare Security Administration, and...
Santen’s Tapcom Administered to First Patient in GBA via Drug Access Policy
Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...
Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...
Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio
China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...
Fosun Pharma Secures Licensing Deal for HCB101 SIRPα-Fc Fusion Protein
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has entered into a licensing...
Zai Lab’s Bemarituzumab Meets Phase III Endpoint in Gastric Cancer Trial
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that its Phase III FORTITUDE-101...
Hengrui Pharmaceuticals’ Aihengping Gains NMPA Approval for Regional Analgesia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...
Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...
Hengrui Pharmaceuticals Gains NMPA Approval for Aisuda in Severe Alopecia Areata
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received additional indication approval from the...
MicroPort NeuroTech’s NUMEN Nest Gains FDA Marketing Approval
China-based MicroPort NeuroTech Limited (HKG: 2172) announced that its NUMEN Nest, an enhanced version of...